Accelerate to discover

Back to filter

Related topics

Observe the movement of live cells that make up living tissue in vivo

IVIM Technology

Apr 8, 2021

IntraVital Microscopy is a technique that enables you to directly observe the movement of live cells that make up...

Cytek webinar : Improved flow cytometry assay resolution with autofluorescence extraction

Cytek Biosciences

Mar 30, 2021

The power of autofluorescence extraction in the detection of dim fluorescence on highly autofluorescent cells, and the...

Unleash Your Illumina Sequencer with TELL-Seq Linked Reads

Sage Science

Mar 24, 2021

Sage Science distributes universal sequencing technology´s TELL-Seq linked-read NGS library prep kits used with very...

Apr 12, 2021

Bruker webinar : High-resolution exploration of ESM-based vascularized tissue-flaps

Bruker Biospin

Mar 22, 2021

By employing a tissue engineering approach based on biological tissue constructs, Dr. Redenski has fabricated composite...

A real time-saver, accurate cell counting in 15 seconds with C100 counter

RWD

Mar 17, 2021

Cell counters are tools for counting live and/or dead cells in a culture. Any researcher who works in a cell culture...

Innovation never takes a break with IncuCyte

Sartorius

Mar 11, 2021

Analyze your cells for days, weeks or even months as they sit stationary in the stable environment of your tissue...

Apr 12, 2021

Imaging Flow Cytometry Luminex learning sessions

Luminex

Mar 5, 2021

Start the new year with new knowledge! Get the most from your Amnis instrument and IDEAS Software with training...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey